Targeted Drug EGFR RTK Inhibitors for NSCLC Market Report

Global and Region Targeted Drug EGFR RTK Inhibitors for NSCLC Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Aug 02, 2022
  • PAGES：150
  • REPORT CODE：GMM986759
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The report details the trend, potential and market size of Targeted Drug EGFR RTK Inhibitors for NSCLC market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Targeted Drug EGFR RTK Inhibitors for NSCLCmarket, defines the market attractiveness level of Targeted Drug EGFR RTK Inhibitors for NSCLC market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Targeted Drug EGFR RTK Inhibitors for NSCLC industry, describes the types of Targeted Drug EGFR RTK Inhibitors for NSCLC market, the applications of major players and the market size, and deeply analyzes the current situation of the global Targeted Drug EGFR RTK Inhibitors for NSCLC market and the development prospects and opportunities of Targeted Drug EGFR RTK Inhibitors for NSCLC industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Targeted Drug EGFR RTK Inhibitors for NSCLC market in Chapter 13.

    By Player:

    • Natco Pharma

    • Drug International Limted

    • Glenmark Pharmaceuticals

    • Hetero Drugs

    • Everest Pharmaceuticals

    • AstraZeneca

    • Zydus Cadila

    • Intas Pharmaceuticals

    • ARIAD Pharmaceuticals (Takeda)

    • Mylan

    • Beacon Pharmaceuticals

    • Beta Pharma

    • Genvio Pharma Limited

    • Pfizer

    • Cipla Pharma

    • Alkem Laboratories

    • Genentech (Roche Group)

    • Boehringer Ingelheim

    • Teva

    • Dr Reddy's Laboratories

    • Incepta Pharmaceuticals Limited

    • Fresenius Kabi India

    • OSI Pharmaceuticals

    • RPG Life Sciences

    • Qilu Pharmaceutical

    By Type:

    • Icotinib

    • Gefitinib

    • Erlotinib

    • Afatinib

    • Osimertinib

    • Brigatinib

    • Other

    By End-User:

    • Squamous Cell Carcinoma of NSCLC

    • Adenocarcinoma of NSCLC

    • Large Cell Carcinoma of NSCLC

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Targeted Drug EGFR RTK Inhibitors for NSCLC Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Targeted Drug EGFR RTK Inhibitors for NSCLC Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Targeted Drug EGFR RTK Inhibitors for NSCLC Market Analysis and Outlook to 2022

    • 7.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)

    • 7.2 United States Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)

    • 7.3 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)

    • 7.4 China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)

    • 7.5 Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)

    • 7.6 India Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)

    • 7.7 South Korea Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption (2017-2022)

    8 Region and Country-wise Targeted Drug EGFR RTK Inhibitors for NSCLC Market Analysis and Outlook to 2028

    • 8.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)

    • 8.2 United States Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)

    • 8.3 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)

    • 8.4 China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)

    • 8.5 Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)

    • 8.6 India Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)

    • 8.7 South Korea Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast (2022-2028)

    9 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Outlook by Types and Applications to 2022

    • 9.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Icotinib Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Gefitinib Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Erlotinib Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Afatinib Consumption and Growth Rate (2017-2022)

      • 9.1.5 Global Osimertinib Consumption and Growth Rate (2017-2022)

      • 9.1.6 Global Brigatinib Consumption and Growth Rate (2017-2022)

      • 9.1.7 Global Other Consumption and Growth Rate (2017-2022)

    • 9.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Squamous Cell Carcinoma of NSCLC Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Adenocarcinoma of NSCLC Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Large Cell Carcinoma of NSCLC Consumption and Growth Rate (2017-2022)

    10 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Outlook by Types and Applications to 2028

    • 10.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Icotinib Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Gefitinib Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global Erlotinib Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.4 Global Afatinib Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.5 Global Osimertinib Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.6 Global Brigatinib Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.7 Global Other Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Squamous Cell Carcinoma of NSCLC Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Adenocarcinoma of NSCLC Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Large Cell Carcinoma of NSCLC Consumption Forecast and Growth Rate (2022-2028)

    11 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Competitive Analysis

    • 14.1 Natco Pharma

      • 14.1.1 Natco Pharma Company Details

      • 14.1.2 Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    • 14.2 Drug International Limted

      • 14.2.1 Drug International Limted Company Details

      • 14.2.2 Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    • 14.3 Glenmark Pharmaceuticals

      • 14.3.1 Glenmark Pharmaceuticals Company Details

      • 14.3.2 Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    • 14.4 Hetero Drugs

      • 14.4.1 Hetero Drugs Company Details

      • 14.4.2 Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    • 14.5 Everest Pharmaceuticals

      • 14.5.1 Everest Pharmaceuticals Company Details

      • 14.5.2 Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    • 14.6 AstraZeneca

      • 14.6.1 AstraZeneca Company Details

      • 14.6.2 AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    • 14.7 Zydus Cadila

      • 14.7.1 Zydus Cadila Company Details

      • 14.7.2 Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    • 14.8 Intas Pharmaceuticals

      • 14.8.1 Intas Pharmaceuticals Company Details

      • 14.8.2 Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    • 14.9 ARIAD Pharmaceuticals (Takeda)

      • 14.9.1 ARIAD Pharmaceuticals (Takeda) Company Details

      • 14.9.2 ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    • 14.10 Mylan

      • 14.10.1 Mylan Company Details

      • 14.10.2 Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.10.3 Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    • 14.11 Beacon Pharmaceuticals

      • 14.11.1 Beacon Pharmaceuticals Company Details

      • 14.11.2 Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.11.3 Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    • 14.12 Beta Pharma

      • 14.12.1 Beta Pharma Company Details

      • 14.12.2 Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.12.3 Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    • 14.13 Genvio Pharma Limited

      • 14.13.1 Genvio Pharma Limited Company Details

      • 14.13.2 Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.13.3 Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    • 14.14 Pfizer

      • 14.14.1 Pfizer Company Details

      • 14.14.2 Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.14.3 Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    • 14.15 Cipla Pharma

      • 14.15.1 Cipla Pharma Company Details

      • 14.15.2 Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.15.3 Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    • 14.16 Alkem Laboratories

      • 14.16.1 Alkem Laboratories Company Details

      • 14.16.2 Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.16.3 Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    • 14.17 Genentech (Roche Group)

      • 14.17.1 Genentech (Roche Group) Company Details

      • 14.17.2 Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.17.3 Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    • 14.18 Boehringer Ingelheim

      • 14.18.1 Boehringer Ingelheim Company Details

      • 14.18.2 Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.18.3 Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    • 14.19 Teva

      • 14.19.1 Teva Company Details

      • 14.19.2 Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.19.3 Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    • 14.20 Dr Reddy's Laboratories

      • 14.20.1 Dr Reddy's Laboratories Company Details

      • 14.20.2 Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.20.3 Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    • 14.21 Incepta Pharmaceuticals Limited

      • 14.21.1 Incepta Pharmaceuticals Limited Company Details

      • 14.21.2 Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.21.3 Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    • 14.22 Fresenius Kabi India

      • 14.22.1 Fresenius Kabi India Company Details

      • 14.22.2 Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.22.3 Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    • 14.23 OSI Pharmaceuticals

      • 14.23.1 OSI Pharmaceuticals Company Details

      • 14.23.2 OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.23.3 OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    • 14.24 RPG Life Sciences

      • 14.24.1 RPG Life Sciences Company Details

      • 14.24.2 RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.24.3 RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    • 14.25 Qilu Pharmaceutical

      • 14.25.1 Qilu Pharmaceutical Company Details

      • 14.25.2 Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

      • 14.25.3 Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Targeted Drug EGFR RTK Inhibitors for NSCLC

    • Figure Targeted Drug EGFR RTK Inhibitors for NSCLC Picture

    • Table Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption by Country (2017-2022)

    • Figure United States Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)

    • Table Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)

    • Figure China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)

    • Figure Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)

    • Figure India Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)

    • Figure South Korea Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)

    • Figure Global Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast by Country (2022-2028)

    • Figure United States Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Icotinib Consumption and Growth Rate (2017-2022)

    • Figure Global Gefitinib Consumption and Growth Rate (2017-2022)

    • Figure Global Erlotinib Consumption and Growth Rate (2017-2022)

    • Figure Global Afatinib Consumption and Growth Rate (2017-2022)

    • Figure Global Osimertinib Consumption and Growth Rate (2017-2022)

    • Figure Global Brigatinib Consumption and Growth Rate (2017-2022)

    • Figure Global Other Consumption and Growth Rate (2017-2022)

    • Figure Global Squamous Cell Carcinoma of NSCLC Consumption and Growth Rate (2017-2022)

    • Figure Global Adenocarcinoma of NSCLC Consumption and Growth Rate (2017-2022)

    • Figure Global Large Cell Carcinoma of NSCLC Consumption and Growth Rate (2017-2022)

    • Figure Global Icotinib Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Gefitinib Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Erlotinib Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Afatinib Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Osimertinib Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Brigatinib Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Other Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Squamous Cell Carcinoma of NSCLC Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Adenocarcinoma of NSCLC Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Large Cell Carcinoma of NSCLC Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Targeted Drug EGFR RTK Inhibitors for NSCLC Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Targeted Drug EGFR RTK Inhibitors for NSCLC Export by Region (Top 5 Countries) (2017-2028)

    • Table Natco Pharma (Foundation Year, Company Profile and etc.)

    • Table Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    • Table Drug International Limted (Foundation Year, Company Profile and etc.)

    • Table Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    • Table Glenmark Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    • Table Hetero Drugs (Foundation Year, Company Profile and etc.)

    • Table Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    • Table Everest Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    • Table AstraZeneca (Foundation Year, Company Profile and etc.)

    • Table AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    • Table Zydus Cadila (Foundation Year, Company Profile and etc.)

    • Table Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    • Table Intas Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    • Table ARIAD Pharmaceuticals (Takeda) (Foundation Year, Company Profile and etc.)

    • Table ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    • Table Mylan (Foundation Year, Company Profile and etc.)

    • Table Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    • Table Beacon Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    • Table Beta Pharma (Foundation Year, Company Profile and etc.)

    • Table Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    • Table Genvio Pharma Limited (Foundation Year, Company Profile and etc.)

    • Table Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    • Table Pfizer (Foundation Year, Company Profile and etc.)

    • Table Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    • Table Cipla Pharma (Foundation Year, Company Profile and etc.)

    • Table Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    • Table Alkem Laboratories (Foundation Year, Company Profile and etc.)

    • Table Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    • Table Genentech (Roche Group) (Foundation Year, Company Profile and etc.)

    • Table Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    • Table Boehringer Ingelheim (Foundation Year, Company Profile and etc.)

    • Table Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    • Table Teva (Foundation Year, Company Profile and etc.)

    • Table Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    • Table Dr Reddy's Laboratories (Foundation Year, Company Profile and etc.)

    • Table Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    • Table Incepta Pharmaceuticals Limited (Foundation Year, Company Profile and etc.)

    • Table Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    • Table Fresenius Kabi India (Foundation Year, Company Profile and etc.)

    • Table Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    • Table OSI Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    • Table RPG Life Sciences (Foundation Year, Company Profile and etc.)

    • Table RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service

    • Table Qilu Pharmaceutical (Foundation Year, Company Profile and etc.)

    • Table Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)

    • Table Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US